Creative Touch Permanent Makeup and Aesthetics

Adipose tissue was once regarded as a passive energy store. It is now understood to be a metabolically active endocrine organ – and in the context of obesity, a dysfunctional one. Hypertrophied adipocytes and the macrophages they recruit into crown-like structures within fat depots produce a sustained efflux of pro-inflammatory mediators, adipokines, and steroid hormones into systemic circulation. The clinical consequence for skin is not a single effect but a compound one: elevated circulating cytokines suppress barrier gene expression; increased oestrogen drives tissue remodelling and fluid retention; impaired microvascular perfusion delays the healing response; and the shared insulin resistance pathway amplifies every glycation and sebogenic mechanism independently described in the Low-Carbohydrate Diet and Blood Sugar Instability entities. Aesthetics treatments do not operate in a metabolically neutral environment – they operate in this one.

The Adipose Inflammatory State

Obesity is associated with a chronic, low-grade inflammatory state driven by the progressive recruitment of macrophages into expanding adipose tissue. As adipocytes hypertrophy, they begin secreting tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in quantities that correlate directly with adipose mass and inversely with insulin sensitivity. A study measuring cytokine expression in adipose tissue from lean and obese subjects found a 7.5-fold increase in TNF-α secretion from adipose tissue in obese versus lean subjects, while plasma IL-6 showed a highly significant inverse relationship with insulin sensitivity (r = −0.71, p < 0.001), with a fivefold difference between the most insulin-resistant and most insulin-sensitive participants. ^[1] CRP, an acute-phase reactant synthesised in response to IL-6 signalling, is reliably elevated in obesity and serves as the accessible clinical marker of this systemic inflammatory background. ^[3]

The skin consequence operates through several parallel pathways. TNF-α and IL-6 directly suppress filaggrin expression in keratinocytes – filaggrin being the structural protein responsible for tight junction formation in the stratum granulosum and the primary determinant of skin barrier competency. ^[4] Reduced filaggrin expression increases transepidermal water loss (TEWL), impairs the natural moisturising factor (NMF) pool, and elevates barrier permeability to allergens and irritants – the same upstream failure responsible for atopic dermatitis and compromised post-procedure barrier recovery. The mechanistic overlap between obesity-driven cytokine elevation and filaggrin suppression explains the well-documented association between obesity and atopic dermatitis severity, and has direct procedural implications: a client with an obesity-related inflammatory background is entering any barrier-disrupting treatment – microneedling, chemical peeling, ablative laser – with a structurally impaired barrier and an elevated systemic inflammatory set-point that will influence recovery kinetics.

Gene expression analysis of skin from obese subjects has confirmed the breadth of these effects at the tissue level: MMP-9 expression was elevated sevenfold in obese subdermal fat, indicating accelerated matrix degradation; EGFL6, an epidermal growth factor modulator that alters insulin action, was increased 8.5-fold; and multiple metabolic and complement-related genes were broadly downregulated. nature.com The net picture is a tissue environment with elevated proteolytic activity, altered growth factor signalling, and reduced complement-mediated immune function – not a favourable background for collagen synthesis or procedural remodelling.

Adipose-Derived Oestrogen Excess

Adipose tissue is the primary site of extragonadal oestrogen synthesis in both postmenopausal women and men. The enzyme aromatase (CYP19A1), expressed in adipocytes and adipose stromal fibroblasts, converts androgen precursors – androstenedione and testosterone – to oestrone and oestradiol. In obesity, aromatase expression is upregulated by the same inflammatory mediators produced by dysfunctional adipose tissue: TNF-α, IL-1β, IL-6, and prostaglandin E2 (PGE2) all stimulate aromatase promoter activity, creating a self-reinforcing cycle where adipose inflammation drives oestrogen production, and elevated oestrogen further dysregulates adipose tissue biology. ^[2]

The skin-relevant consequences of elevated adipose-derived oestrogen are multiple and depend on sex and hormonal context. In postmenopausal women, aromatase-driven oestrogen from adipose tissue partially replaces ovarian oestrogen, moderating some aspects of skin thinning and collagen loss – a net effect that has been described as partially protective for skin ageing in obese postmenopausal women compared to lean counterparts, though this is offset by the inflammatory and barrier consequences described above. In premenopausal women and in men, elevated adipose-derived oestrogen disrupts the androgen-to-oestrogen ratio, contributing to hormonal skin presentations including altered sebum patterns, follicular sensitivity changes, and in men, gynaecomastia and redistribution of subcutaneous fat. The aromatase upregulation also explains why weight loss in obese individuals produces more pronounced hormonal recalibration than weight loss in individuals with less adipose tissue.

Wound Healing and Treatment Response

Obesity impairs cutaneous wound healing through a convergent set of mechanisms that are directly relevant to procedural aesthetics. The inflammatory set-point issue is the first: the chronic cytokine elevation described above produces a prolonged and dysregulated inflammatory phase following any cutaneous injury, delaying the transition to proliferative repair. The second mechanism is microvascular: adipose tissue expansion reduces the vascular density of subcutaneous tissue relative to tissue volume, and the resulting relative hypoxia impairs fibroblast collagen synthesis – collagen production requiring molecular oxygen as a cofactor for prolyl hydroxylase activity. dermatoljournal.com A third mechanism operates through adiponectin: adiponectin, an anti-inflammatory adipokine that promotes angiogenesis and keratinocyte migration, is paradoxically decreased in obesity despite the increase in total adipose mass – with adiponectin deficiency impairing both re-epithelialisation and the angiogenic component of repair. dermatoljournal.com

The procedural implication is a predictable pattern of underperformance: slower re-epithelialisation after ablative treatments, higher infection risk, prolonged erythema and oedema, reduced collagen remodelling output from RF microneedling or fractional laser, and a lower margin of safety for deep or aggressive protocols. This is not a contraindication to treatment, but it is a risk-stratification and expectation-management consideration that should be addressed in the consultation – particularly given that many clients presenting for body contouring, skin tightening, or acne treatment in the context of obesity or recent significant weight loss are entering a tissue environment that is neither inflammatory-neutral nor repair-optimal.

GLP-1 Medications and the Transitional State

GLP-1 receptor agonists are now the primary clinical tool for managing obesity, producing mean weight losses of 15–22% of body weight over 68–72 weeks. The metabolic benefits – reduced systemic inflammation, improved insulin sensitivity, lower circulating IL-6 and CRP – are substantial and begin within weeks of initiating treatment, ahead of significant weight loss. From an aesthetics perspective, successful GLP-1-mediated weight loss represents a transition from an obesity-inflammatory tissue environment toward a lower-inflammation state – broadly favourable for skin biology – but the transition introduces its own specific risks.

Rapid weight loss at the rates produced by GLP-1 medications preferentially reduces subcutaneous fat volume, including the subdermal fat layer that provides structural support to overlying skin. Combined with the protein inadequacy documented in GLP-1 users – which compromises the collagen and elastin synthesis needed to maintain skin tensile architecture – this produces the skin laxity, hollowing, and surface textural changes that have become widely discussed as GLP-1 skin consequences. The tissue biology during active GLP-1-mediated weight loss is therefore a transitional state: the chronic inflammatory drivers of obesity are reducing, but the structural substrate for skin quality is also diminishing in parallel, at a rate that outpaces the skin’s remodelling capacity if protein intake and collagen synthesis support are inadequate. Managing this transition – supporting synthesis while the inflammatory burden resolves – is a clinically distinct challenge from managing either stable obesity or stable healthy weight.